Have you read this JDD consensus on advanced topical nonsteroidal therapies for atopic dermatitis? Dive into this recent article from the March issue! A seven-dermatologist expert panel used a structured…
Read More
From the Vault: A popular consensus paper recommends newborn‑to‑child barrier care with ceramide‑containing moisturizers to delay flares and reduce steroid need We pulled this widely read JDD article because it…
Read More
Breakthroughs in atopic dermatitis are redefining treatment from the inside out. Discover how new data on race, microbes, and patient preferences are transforming the way we think about AD. In…
Read More
Think beyond inflammation: SAIGE framing reframes pediatric AD prevention and care A seven‑expert global panel of pediatric dermatologists and dermatologists used a modified Delphi process to produce five consensus statements…
Read More
Dupilumab delivers — but many patients need more than monotherapy over time In a US retrospective cohort (OM1 PremiOM™ AD) of 5,200 patients who started dupilumab between 2017-2021 (208 children, 430…
Read More
Rethinking AD — Beyond Inflammation Atopic dermatitis remains common and stubborn, especially in pediatric patients, because inflammation is only one part of a self‑reinforcing loop that includes microbiome disruption, neuroimmune…
Read More
Curated by the JDD Editors Missed any of our October highlights? October is our Atopic Dermatitis focused issue–start to dive in! Catch up with this curated roundup from the JDD…
Read More
Fast itch relief and comparable skin clearance at week 4 - a nonsteroidal option to note for mild-moderate AD In a phase 2, dose‑ranging trial, twice‑daily 1.5% ruxolitinib cream matched…
Read More
A simple 1% colloidal oatmeal regimen cut itch and improved eczema scores within days in toddlers A small open‑label study in children aged 3-72 months tested a twice‑daily 1% colloidal…
Read More
When One Target Isn’t Enough — Dual Therapy Clears Refractory ADW An adolescent with persistent, widespread atopic dermatitis failed topical therapy and dupilumab, then achieved only partial control on upadacitinib…
Read More
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…
Read More
Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…
Read More
